Isomorphic Labs Raises 5 Billion Dollars to Push AI-Designed Drugs Toward Human Trials
Isomorphic Labs, the London-based company that uses artificial intelligence to design new medicines, announced a 5 billion dollar Series C funding round on Tuesday, November 17. The company described the round as oversubscribed. Greenoaks and Sequoia Capital co-led the financing, Andreessen Horowitz joined as a new investor, and Alphabet made an additional significant investment. All of the company's existing investors also took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.